Risankizumab

Risankizumab Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Risankizumab is being investigated for atopic dermatitis.

Risankizumab Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Risankizumab Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+1-781-999-5354; +17819995354	marketing@targetmol.com	United States	32435	58
Aladdin Scientific		tp@aladdinsci.com	United States	57505	58
Wuhan Sunrise Technology Development Co., Ltd.	27-027-83314682 13554138826	whsrtech@vip.163.com	China	246	62
Shanghai YuanYe Biotechnology Co., Ltd.	021-61312847; 18021002903	3008007409@qq.com	China	71826	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	8000	62
Hefei Hirisun Pharmatech Co., Ltd.	+86-0551-62678551 +86-15056975894	sales@hirisunpharm.com	China	176	55
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1566	58
Jiangsu Greature Bio-Medicine Co., Ltd.	0512-85557988 18662338937	frank.wang@greature.com.cn	China	147	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10308	58
Bide Pharmatech Ltd.	400-1647117 13681763483	product02@bidepharm.com	China	59936	58

---

• Immunoglobulin G1, anti-(human interleukin 23 subunit p19) (human-Mus musculus heavy chain), disulfide with human-Mus musculus κ-chain, dimer
• Risankizumab
• Research Grade Risankizumab (DHJ63101)
• Risankizumab (anti-IL-23)
• Risankizumab rzaa|||SKYRIZI|||ABBV 066|||BI-655066
• Research Grade Risankizumab
• 1612838-76-2